. Scientific Frontline: LMP1 Transcription Factors Activate Antitumor Immunity

Monday, November 16, 2026

LMP1 Transcription Factors Activate Antitumor Immunity

LMP1 activates Spi-B and IRF1 to promote MHC class I and CD80, enhancing CD8+ T-cell immunity in a mouse tumor model.

LMP1 activates Spi-B and IRF1 in tumor cells, promoting MHC class I and CD80 expression and enhancing CD8+ T-cell-mediated antitumor immunity. This mechanism suggests a potential strategy for turning immune-cold tumors into immunologically active tumors.
Image Credit: Tomoharu Yasuda / Hiroshima University

Scientific Frontline: Extended "At a Glance" Summary: LMP1 and Tumor Immunogenicity

The Core Concept: Researchers have identified that two transcription factors, Spi-B and IRF1, mediate the antitumor immune effects of the Epstein-Barr virus protein LMP1, effectively turning "immune-cold" tumors into targets for CD8+ T cells.

Key Distinction/Mechanism: While the viral protein LMP1 has dual cancer-promoting and immune-stimulating properties, expressing only its downstream targets, Spi-B and IRF1, successfully activated CD8+ T cells and suppressed tumor growth in mouse models without the need for the cancer-causing viral protein itself.

Origin/History: The research, published in Cell Reports by Hiroshima University scientists, builds on previous findings that LMP1 can make infected B cells more recognizable to the immune system.

Major Frameworks/Components:

  • LMP1: An Epstein-Barr virus protein that increases MHC class I expression in solid tumor cell lines.
  • Spi-B: A transcription factor that upregulates CD80, a vital co-stimulatory signal for T cell activation.
  • IRF1: A transcription factor that increases MHC class I expression, allowing antigens to be displayed for CD8+ T cells.
  • Endogenous Retroviruses: LMP1 increases the presentation of antigens from these ancient viral genome remnants, helping activate tumor-reactive CD8+ T cells in mouse melanoma models.

Branches of Science: Immunology, Molecular Oncology, Virology.

Future Application: The research team plans to develop an mRNA delivery system to introduce Spi-B and IRF1 directly into human tumors, aiming to strengthen antitumor immune responses safely.

Why It Matters: This mechanism provides a potential blueprint for immunotherapies that can convert immunologically inactive tumors into active ones, enhancing the body's natural ability to recognize and destroy cancer cells without the risks associated with utilizing viral proteins.

The Epstein-Barr virus protein LMP1 exhibits dual properties: it acts as an oncogenic driver promoting cancer progression, while also possessing immunogenic capabilities that can stimulate antitumor immune responses. In a study published in Cell Reports, researchers traced key parts of that antitumor effect to the transcription factors Spi-B and IRF1, showing that expressing the two without LMP1 activated CD8+ T cells and suppressed tumor growth in mice.

Scientists at Hiroshima University have traced the key antitumor immune effects of LMP1, a cancer-promoting Epstein-Barr virus protein, to two transcription factors: Spi-B and IRF1. They found that expressing the two together enhanced the immunogenicity of the tumor cells, facilitating immune system recognition and enabling the activation of CD8+ T cells without using the viral protein itself.

The findings, published in Cell Reports, build on an unusual property of LMP1. Previous research established that the viral protein induces oncogenic transformation in infected B cells, while simultaneously enhancing their susceptibility to T-cell-mediated recognition and clearance.

The researchers asked whether LMP1 could produce similar immune effects in solid tumor cells, and which downstream factors were responsible. "LMP1 has two contrasting faces, much like Dr. Jekyll and Mr. Hyde," said corresponding author Tomoharu Yasuda, a professor at Hiroshima University's Graduate School of Biomedical and Health Sciences.

In laboratory experiments, LMP1 increased MHC class I expression across several solid tumor cell lines. It also increased molecules involved in T-cell activation in some tumor models. In mouse melanoma cells, LMP1 increased the presentation of antigens derived from endogenous retroviruses—remnants of ancient viral infections embedded in the genome—helping activate tumor-reactive CD8+ T cells. The researchers then traced key parts of the immune effects of LMP1 to two transcription factors, Spi-B and IRF1.

Spi-B upregulated the expression of the co-stimulatory molecule CD80, whereas IRF1 increased the expression of MHC class I. Together, the two factors made tumor cells better able to present antigens and stimulate CD8+ T-cell responses.

Expressing Spi-B and IRF1 together reproduced the key immune effects of LMP1 without requiring the cancer-promoting viral protein itself. Expressing both factors increased CD8+ T-cell responses and suppressed tumor growth in mice.

"In a sense, we have found a way to bring out Dr. Jekyll while leaving Mr. Hyde behind," Yasuda said.

The findings suggest a potential therapeutic strategy to convert immunologically "cold" tumors into highly immunogenic targets capable of robust T-cell activation. The approach remains experimental. The tumor suppression results were demonstrated in mice, and the specific endogenous retrovirus antigen examined was mouse-specific. Further studies will be needed to determine whether targeting Spi-B and IRF1 can produce similar effects safely and effectively in human tumors.

The researchers now plan to develop a messenger RNA, or mRNA, approach to deliver Spi-B and IRF1 into tumors. Their goal is to test whether the two factors can strengthen antitumor immune responses without introducing LMP1 itself.

Funding: This work was supported by the Sasakawa Scientific Research Grant from The Japan Science Society; JST SPRING, grant no. JPMJSP2132; Grant-in-Aid for JSPS Fellows 24KJ1735 to K.Y.; the JSPS KAKENHI under grant nos. JP18H02669, JP19K22538, JP21H02751, JP24K11047, and JP25H01061; AMED P-PROMOTE grant no. 25ama221344; JSPS Program for Forming Japan’s Peak Research Universities (JSPS J-PEAKS); JST grant no. JPMJPF2010 (COI-NEXT); JST Program for co-creating startup ecosystem grant no. JPMJSFS1A8; Research Funding for Longevity Sciences from the National Center for Geriatrics and Gerontology; and the Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science to T.Y.

Published in journal: Cell Reports

Title: Spi-B and IRF1 activate tumor immunogenicity downstream of the Epstein-Barr virus protein LMP1

Authors: Keita Yamane, Yohei Kawano, Shun Ohki, Katsuki Matayoshi, Nagisa Morihara, Hitoshi Azuma, Yusei Ota, Yasuo Kitajima, Tomohiro Asai, and Tomoharu Yasuda

Source/Credit: Hiroshima University

Edited by: Scientific Frontline

Reference Number: imgy111626_01

Privacy Policy | Terms of Service | Contact Us